Incidence, risk factors, survival and treatment of bone metastases from colorectal cancer:Systematic review by Christensen, Troels Dreier et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Incidence, risk factors, survival and treatment of bone metastases from colorectal
cancer
Christensen, Troels Dreier; Jensen, Sandra Galinska; Larsen, Finn Ole; Nielsen, Dorte Lisbet
Published in:
Journal of Bone Oncology
DOI:
10.1016/j.jbo.2018.09.009
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Christensen, T. D., Jensen, S. G., Larsen, F. O., & Nielsen, D. L. (2018). Incidence, risk factors, survival and
treatment of bone metastases from colorectal cancer: Systematic review. Journal of Bone Oncology, 13, 97-105.
https://doi.org/10.1016/j.jbo.2018.09.009
Download date: 03. Feb. 2020
Contents lists available at ScienceDirect
Journal of Bone Oncology
journal homepage: www.elsevier.com/locate/jbo
Review Article
Systematic review: Incidence, risk factors, survival and treatment of bone
metastases from colorectal cancer
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Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark
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A B S T R A C T
Background: Bones are not considered a frequent metastatic site in patients with colorectal cancer (CRC). The
purpose of the present study was to determine the incidence of bone metastases (BM) in CRC, to identify possible
risk factors for BM, survival after BM, and eﬀect of treatment of BM including antiresorptive treatment.
Material and methods: A computer-based literature search was carried out using PubMed and EMBASE.
Results: We included 29 studies. One randomized placebo controlled trial (RCT) study, two autopsy studies, ﬁve
register studies, and twenty retrospective cohort studies. The studies described diﬀerent cohorts making direct
comparison diﬃcult. Three studies analysed the eﬀect of diﬀerent treatments for BM including one RCT study.
Conclusion: The incidence of bone metastases was 3–7% in patients with CRC, and it was not possible to detect
an increase in incidence over time. The most well established risk factors for BM are rectal cancer, having lymph
node invasion at surgery of primary tumor, and lung metastases at any time. Other risk factors such as RAS
mutation status have been suggested but results are not conclusive. Survival ranges from 5 to 21 months after
diagnosis of BM depending on cohort, with survival of about 8 months in unselected patients. Several variables
have been suggested as potential prognostic markers but are all poorly investigated. Treatment of BM is not well
investigated, though patients seem to beneﬁt from bisphosphonate treatment with regard to lower risk of skeletal
related events. This review highlights the need for new research in the area.
1. Background
Colorectal cancer (CRC) is the third most commonly diagnosed
cancer in males and the second in females, with an estimated 1.4 mil-
lion cases worldwide. In 2012 metastatic CRC (mCRC) was the cause of
death in 693,900 patients [1], despite the advantages in screening,
diagnosis and improved surgical and medical treatments.
About 20% of patients with CRC have already distant metastases at
presentation [2] and totally 50% of patients with CRC will develop
metastatic disease [3]. Moreover, a recent Norwegian study showed
that 15.6% patients with CRC, who were considered surgically cured,
had recurrent cancers including distant metastases during a ﬁve year
follow up [4].
Today little is known about bone metastases (BM) from CRC. BM are
considered frequent among patients with breast cancer, prostate cancer
and lung cancer [5]. Bones are in fact the most frequent metastatic site
among patients with breast cancer since up to 70% of all patients with
disseminated breast cancer develop BM [6]. In breast, prostate and lung
cancer, the antiresorptive treatment, bisphosphonates and denosumab,
reduces further progression in bones and prevents complications by
reducing the upregulated osteoclast activity caused by the metastasis.
The outcome is fewer skeletal related events (SRE), and in the long term
the antiresorptive treatment has an analgesic eﬀect [7–10].
Since the relative survival of CRC has increased over the recent
decades [11], we expect to see an increasing number of patients in our
clinical practice with BM from CRC. For that reason, basic knowledge of
the incidence, possible risk factors, survival and treatment of BM from
CRC is essential, hence this review was made.
2. Method
In order to systematically review the literature about BM from CRC
we completed the following search in PubMed on the 24th of September
2017 which resulted in 1064 hits: (((Bone AND metastases)) OR
("Neoplasm Metastasis"[Mesh] AND Bone)) OR (("Neoplasm
Metastasis"[Mesh]) AND ("Bone and Bones"[Mesh]))) OR "bone metas-
tases") OR "bone metastasis")) AND (((("rectal cancer") OR "colon
cancer") OR "colorectal cancer") OR "Colorectal Neoplasms"[Mesh]).
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The following search was performed in EMBASE on 18th November
2017 resulting in 1374 hits: ((rectum cancer or rectum tumor or rectum
carcinoma or colorectal cancer or colon carcinoma or colon tumor or
colon cancer) and bone metastasis).
To ensure a complete search we also searched for “Metastatic pat-
tern AND (((("rectal cancer") OR "colon cancer") OR "colorectal cancer")
OR "Colorectal Neoplasms"[Mesh])” in PubMed (1013 hits) and
((Rectum cancer or rectum tumor or rectum carcinoma or colorectal
cancer or colon carcinoma or colon tumor or colon cancer) and meta-
static pattern) in EMBASE (52 hits).
The searches were last updated 2nd July 2018.
Furthermore, we searched reference list of relevant studies.
We included human studies written in English describing patients
with BM from CRC. The studies should include at least 10 patients with
BM from CRC. Reviews, case stories and studies published before 1975
were excluded. In total 29 studies were identiﬁed through our search of
the literature [12–40].
The following information was extracted; incidence of BM, survival
after BM diagnosis, treatment of BM and follow-up. If the authors did
not display the incidence, we calculated it by dividing the number of
patients with BM with the number of patients with CRC.
Furthermore, results of any statistical analysis regarding risk factors
for developing BM, risk factors for poor survival after BM, and treat-
ment eﬃcacy were extracted.
3. Results and discussion
We included 29 studies (Table 1). One study was a randomized
placebo controlled trial (RCT) [40], two were autopsy studies [38,39],
ﬁve were register studies [33–37]. Twenty-one were retrospective co-
hort studies [12–32]. Six studies included unselected cohorts of patients
with CRC [12–15,33,34]. The remaining studies included various co-
horts of patients, for example cohorts only including patients with
mCRC, CRC patients who underwent surgery, patients with adeno-
carcinoma or only rectal cancer patients [1–32,35-40]. Furthermore,
most studies did not report the exact follow-up period and those that
did had diﬀerent follow-up periods. This made a direct comparison
across studies diﬃcult and interpretation of results challenging.
3.1. Incidence of BM
Twenty-seven of the studies reported an incidence of BM among
their patients. The incidence of BM among the various subpopulations
of CRC patients is presented in Table 1.
The incidence of BM in unselected patients with CRC was described
in three retrospective cohort studies [13–15] and two large register
studies [33,34] and ranged from 2.9% to 6.6%. The distribution of stage
and exact follow-up period in these studies were not accounted for. A
sixth study followed all patients until death, but unfortunately, they did
not provide an exact incidence. However, they stated that 264 patients
among more than 2500 patients developed BM giving an incidence
around 10% [12]. As expected a higher incidence of BM was generally
found when only including patients with mCRC. Two cohort studies
described an incidence of BM of 7% and 6.9% among these patients
[26,27] and the register study by Riihimaki et al. reported an incidence
of 9.3% [34] A fourth study presented an incidence of 10.4% in a po-
pulation of patients with mCRC adenocarcinoma [28]. Most of the
studies might have underestimated the true incidence. Firstly, most
studies did not report the exact follow-up period, and only one study
reported that they followed patients until death. Secondly, all studies
were retrospective or register based and mostly based on routine
follow-up schemes, which not necessarily would capture asymptomatic
BM.
Two autopsy studies also presented an incidence of BM among pa-
tients with CRC ranging from 1.7% in a study by Hugen et al. [38] to
23% in a study by Katoh et al. [39]. However, in both studies there was
a potential heavy selection bias since autopsies were not described as
being performed on all patients but only after request from doctors or
patients. Therefore, these results should be interpreted with caution.
It has been suggested that the incidence of BM from CRC is in-
creasing due to better diagnostics options and CRC patients living
longer, but so far this has remained as speculations. In this review we
were not able to assess if the incidence varied over time, due to dif-
ferences in patient populations and overlap in time periods for data
collection in the included studies.
3.2. Risk factors for BM
Fifteen studies described a statistical analysis of potential risk fac-
tors for BM [12,15,16,18,19,22,25,28,30–32,34,35,38,39]. Summary of
their results is presented in Table 2. All studies were retrospective and
they described diﬀerent cohorts making comparison of the results dif-
ﬁcult.
3.2.1. Primary tumor location
From the studies included in this review it seems likely that location
of primary tumor aﬀects the likelihood of BM, with an increasing risk of
BM the more distal the tumor is located.
Eight out of twelve studies that compared the risk of BM among
rectal and colon cancer patients [16,19,22,25,28,30,34,35] identiﬁed
an increased risk among patients with rectal cancer, and none of the
four remaining reported the reverse association [12,32,38,39]. Five
studies presented results of multivariable analysis and in all studies
rectal cancer was identiﬁed as an independent risk factor for BM
[15,16,19,22,34]. The OR for BM among patients with rectal cancer
compared to colon cancer was on multivariable analysis 1.5
(CI 95% = 1.4–1.7) in a large register study by Riihimäki et al. [34],
and between 2.0 and 2.4 in three retrospective cohort studies
[15,19,22]. Sundermeyer et al. did only report p values from their
multivariable analysis [28].
The speciﬁc location colon or rectum might also aﬀect the risk of
BM. A study by Chiang et al. which only included patients with rectal
cancer, identiﬁed an increased incidence of BM in distal rectum
(11.11%), compared to the middle rectum (6.95%) and in the proximal
rectum (3.44%) (p < 0.001) [25]. A similar result among colon cancer
patients was observed by Riihimäki et al. [34]. They identiﬁed an OR
for developing BM of 1.2 (CI 95% = 1.1–1.4) for patients with distal
colon cancer opposed to proximal cancer.
A potential bias of the result could be that direct invasion of the
bone was included as bone metastases, none of the studies reported that
they excluded direct invasion in their analysis. The pattern of metas-
tases could be explained by Batson's venous plexus, a network of val-
veless veins that connect the deep pelvic and thoracic veins to the in-
ternal vertebral venous system [20,30,39,41].
3.2.2. Primary tumor stage
No ﬁrm conclusions can be made regarding potential association
between primary tumor stage and risk of BM. A study by Sundemeyer
et al. conducted on mCRC patients, found a signiﬁcant association be-
tween incidence of BM and early stage cancer on multivariable analysis
[28].
Oppositely, Sun et al. and Zhenghong et al. identiﬁed a signiﬁcantly
increasing incidence of BM with increasing stage in univariate but not
multivariate analysis. Both also included patients with CRC who did not
developed metastases, and therefore the association found on uni-
variate analysis most likely reﬂects the increased risk of all metastases
in higher stages [15,19]. Oppositely, two cohort studies found no as-
sociation [12,16].
3.2.3. Histological type of CRC and mutation status
Results regarding primary tumor grade (well diﬀerentiated, mod-
erately diﬀerentiated, poorly diﬀerentiated or undiﬀerentiated) and
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Table 1
Studies included.
AuthorYearCountry Years Patients No. CRC No. BM Incidence of
BM (%)
95% CI
(%)
Survival after
BM diagnosis
Follow up
Retrospective studies
All cases diagnosed with
CRC
Santini et al.
2012
Italy [12]
1985-2009 All cases with CRC >2500 264 ∼10 9.4 -
11.8
Median 7
months
NR – all dead at last
follow up
Portales et al.
2015
France [13]
1996-2006 All cases with CRC 2434 110 4.5 3.7 –
5.4
Median 9.4
months
-
Bonnheim et al.
1986
USA [14]
1970-1980 All cases with CRC 1406 66 4.7 3.6 -
5.9
Median 7
months
-
Zhenghong et al. 2017
China [15]
2006-2015 All cases with CRC 2066 102 4.9 4.0 –
6.0
- -
Selected patients with CRC
Li et al. 2017
China [16]
Underwent radical surgery. TanyNanyM0 1749 50 2.9 2.2 -
3.8
- 5 years
Baek et al
2016
South Korea [17]
2007-2013 Underwent surgery
(including surgery for stage 4)
5479 63 1.2 0.9 -
1.5
Median: 17.8 Mean 19.6 months
Lan et al. 2015 Taiwan
[18]
2000-2010 Underwent surgery (including surgery
for stage 4)
1492 20a 1.3 0.9 -
0.21
- Median 69.7 months
Sun et al.
2015
China [19]
2004-2009 Underwent radical surgery (including
surgery for stage 4)
Adenocarcinoma
No BM at primary surgery
516 31 6.0 4.1 -
8.4
- Median 69.5 months
Jimi et al.
2013
Japan [20]
1993-2008 Underwent surgery
(including surgery for stage 4)
627 24 3.8 2.5 -
5.6
Median 6
months
-
Nozue et al.
2002
Japan [21]
Not
reported
Underwent surgery
(including surgery for stage 4)
928 12 1.3 1 - 2.2 Median 5
months
-
Liu et al.
2016
China [22]
2006-2014 Underwent surgery
(including surgery for stage 4)
10,132 242 2.4 2.1 -
2.7
Median 15.6
months
Median 21.1 months
Roth et al.
2009
USA [23]
2000-2008 Only patients with CRC and a PET/CT 252 14 5.5 3.1 -
9.1
Mean 15.9
months
Mean 38 months
Amri et al.
2015
USA [24]
2004-2011 CC – patients with single segment
resection**
974 - Right colon:
1.4
Left colon:
0
Sigmoid: 1.9
- - Median
Right colon: 42 months
Left colon:
45 months
Sigmoid:
45 months
Chiang et al.
2014
Taiwan [25]
2002-2006 RC; T3/T4 - underwent surgery M0; No
preoperative radiation or chemotherapy
884 51 5.8 4.3 -
7.5
- Mean 77.8 months
All cases with mCRC
Patanaphan et al.
1993
USA [26]
1979-1982 mCRC 163 11 7 3.4 -
11.8
Median 10
months
-
Besbeas et al.
1977
USA [27]
1960-1970 mCRC 765 53 6.9 5.2 -
8.9
Mean 13.2
months
-
Selected patients with
mCRC
Sundemeyer et al.
2005
USA [28]
1993-2002 mCRC; adenocarcinoma 1020 106 10.4 8.6 -
12.4
Median 21
months
-
Holch et al.
2017
Germany [29]
2007-2014 mCRC, adenocarcinoma, received
treatment
385 - - - - Until diagnosis of mCRC
Yeager et al.
2015
USA [30]
2008-2012 mCRC - genotyped tumors 918 130 14.2 12.1
-16.6
- -
Kemeny et al
2014
USA [31]
2003-2[27]
013
mCRC – treated with liver resection,
HAI and systemic chemotherapy.
available KRAS data
169 - KRAS WT 2
KRAS MUT
13.4
- - Median
44.3 months
Christensen et al.
2018
Denmark [32]
2005 - 2008 mCRC treated with cetuximab and
irinotecan as third line treatment
480 65 13.5 10.7 -
16.9
- Median 25.2 months
(continued on next page)
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risk of BM is inconclusive. Four studies of which three were conducted
on selected cohorts, including one autopsy study, found no association
[19,22,39]. However, a study by Santini et al. including 269 patients
with BM found an association with poor diﬀerentiated tumors having
the shortest time (6 months) to BM and well diﬀerentiated the longest
(33 months). They did not include undiﬀerentiated tumors in analysis
[12]. The association between poorly diﬀerentiated tumor and BM are
also observed in other tumor types e.g. gastric cancer has shown a re-
lationship between poorly diﬀerentiated tumors and BM [42].
Signet-ring cell carcinoma seems to be associated with increased
likelihood of BM though it is not well investigated. Whereas the other
histological subtypes have not been found to aﬀect likelihood of BM. Six
studies performed a statistical analysis of the association between BM
and histological types of CRC. The autopsy studies by Katoh et al. and
Hugen et al. were the only two studies that performed separate analysis
for signet-ring cell carcinoma compared to the other types. Both studies
observed that signet-ring cell carcinoma showed a signiﬁcantly higher
incidence of BM than mucinous adenocarcinoma and adenocarcinoma
[38,39].
The remaining four studies only compared adenocarcinoma to
mucinous adenocarcinoma or adenocarcinoma to mucinous adeno-
carcinoma and signet ring carcinoma combined. None of the four found
a signiﬁcant association with risk of BM [12,16,22,34].
A hypothesis is that diﬀerent molecular patterns of the cancer ex-
plain the pattern of metastases. Thus, genetic alterations in the tumor
could possibly increase the ability of the tumor to seed certain organs
such as the bone, brain or lung. RAS mutations are established pre-
dictors of poor response to anti-EGFR therapy and are associated with
aggressive tumor biology [31,43,44]. PIK3CA, BRAF, and RAS muta-
tions are the only mutations having been assessed for association with
BM development. Only RAS mutations have been found to be a po-
tential risk factor, though evidence is low and data conﬂicting.
Four studies have looked at whether RAS mutations (KRAS and
NRAS) are associated with BM. All studies were conducted on selected
and not comparable cohorts and the results were therefore hard to
compare [18,30–32]. The study by Yaeger et al. was the largest of the
four, and conducted on unselected mCRC patients as opposed to the
three others. They identiﬁed a signiﬁcant association on multivariable
analysis between RAS mutation and BM with a hazard ratio (HR) of
1.62 (CI 95% = 1.1–2.3) [30]. However, RAS mutation status was used
to guide anti-EGFR therapy which could be a potential confounder for
the association between RAS and BM development [45]. Kemeny et al.
only included KRAS exon 2 mutation but also identiﬁed a signiﬁcantly
higher cumulative incidence of BM among mutated compared to wild
type in univariate analysis [31].
The two remaining studies did not ﬁnd a signiﬁcant association
between RASmutation and BM. However, one only included metastases
at diagnosis of metastatic disease [18], and the other was conducted on
a selected cohort of patients who all received the same third line
treatment which might have confounded a potential association [32].
The association between RAS mutation and BM could be due to
diﬀerent gene expression and protein activations in cells with RAS
mutation compared to RAS wildtype cells [45]. Another explanation
could be changes in exosome composition. The exosome protein ex-
pression, including integrin expression, is markedly diﬀerent between
RAS wildtype and RAS mutant colon cancer cells [46], and studies have
shown exosomal protein expression pattern to be important for organ-
speciﬁc metastasis by directing creation of premetastatic niches [47].
Especially exosomal integrin was reported to have a crucial role in di-
recting metastases to the bone [48].
3.2.4. Metastases at other sites
Having lymph node metastases at primary surgery and lung me-
tastases at any time are identiﬁed as potential risk factors for devel-
oping BM. For liver metastases the results were inconclusive.
Having lymph node metastases at primary tumor surgery were
statistically signiﬁcant associated with increased risk of later develop-
ment of BM in two studies, that both only included patients who
Table 1 (continued)
AuthorYearCountry Years Patients No. CRC No. BM Incidence of
BM (%)
95% CI
(%)
Survival after
BM diagnosis
Follow up
Register studies
Kanthan et al.
1999
Canada [33]
1970-1995 All cases with CRC 5352 355 6.6 6 - 7.3 5-year survival:
16 – 38 %b
-
Riihimäki et al. 2016
Sweden [34]
2002-2012 All cases with CRC 49,096 1398 2.9 2.7 -
3.0
Median 5.5
monthsc
-
Qui et al.
2015
USA [35]
2010-2011 All cases with CRC, adenocarcinoma 46,027 356 0.8 0.7 -
0.9
1-year survival
36.2 %
Only at time of diagnosis
of CRC
Van Gestel et al. 2014
Nederlands [36]
2003-2008 CRC; TanyNanyM0 and underwent
surgery
5671 157 3.0 2.4 -
3.2
- Median 5.0 years – only
sites at diagnosis of
mCRC included.
Khattak et al.
2012
Australia [37]
2006-2011 mCRC – only single site metastases 1207 32 2.7 1.8 -
3.7
Median 5.1
months
-
Autopsy studies
Hugen et al.
2014
Netherlands [38]
1991-2010 Autopsy, CRC 5817 103 1.7 - - -
Katoh et al.
1995
Japan [39]
1970-1987 Clinical and autopsy reports 118 28 23.7 16.4 -
32.4
- -
Randomized study
Heras
2007
Greece [40]
- mCRC, BM 73 73 - - - -
Abbreviations: BM=Bone metastases. CRC= colorectal cancer, mCRC=metastatic colorectal cancer, CC= colon cancer, RC= rectum cancer, T= tumor size,
N= lymph node status, M=distant metastases, HAI=Hepatic artery chemo infusion.
a Only initial site of metastases.
b 5 year survival: BM and other metastases 16%, BM only 38%.
c Survival for patients with BM only.
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underwent radical surgery [16,19]. Sun et al. identiﬁed an OR of 2.0
(CI 95%= 1.3–3.1) in multivariable analysis [19], and likewise Li et al.
found a comparable OR of 2.3 (CI 95% = 1.3–4.1) [16]. Santini et al.
found that patients who were lymph node positive at primary surgery
had a median time to BM of only 13 months compared to 20 months
among lymph node negative patients. However, the association was not
statistically signiﬁcant [12]. None of the above mentioned studies as-
sessed whether lymph node involvement speciﬁcally increases the risk
of BM or the association just reﬂects the association between lymph
node status and increased risk of distant metastases. No studies have
Table 2
Risk factors for bone metastases.
Author Type of analysisa Factors associated with increased risk of
bone metastases
Other variable included in analysis but no association
with bone metastases identiﬁed
Santini et al. [12] Univariate Kaplan Meier estimate among (only
including patients with BM)
Primary tumor grade (Poor grade). Primary tumor site,
Primary tumor stage,
Primary tumor histology,
Lymph node status,
Use of adjuvant chemotherapy.
Zhenghong et al. [15] Multivariate logistic regression Rectal cancer,
Lung metastases,
CEA > 5µg/l.
Gender,
Primary tumor histology,
Primary tumor stage,
Initial treatment,
Liver metastases.
Li et al. [16] Multivariate logistic regression Rectal cancer,
Lymph node met. at primary CRC
surgery,
Metachronous lung met.
Age,
Gender,
Primary tumor histology,
Primary tumor stage,
CA199.
Lan et al. [18] Univariate Chi Square Test None. RAS mutation status,
PIK3CA mutation status.
Sun et al. [19] Multivariate logistic regression Rectal cancer,
Lymph node met. at primary CRC
surgery.
Age,
Gender,
Albumin level,
Hemoglobin,
CEA,
Transfusion,
Primary tumor size,
Primary tumor grade,
Primary tumor stage,
Primary tumor Invasion,
Metastasis at diagnosis of CRC.
Liu et al. [22] Univariate Chi Square test Rectal cancer,
Male.
Age,
Primary tumor grade,
Tumor histology.
Chiang et al. [25] Univariate Kaplan Meier estimate Middle and distal as opposed to proximal
rectal cancer.
None.
Sundemeyer et al. [28] Multivariate logistic regression Rectal cancer,
High number of systemic therapies,
Lung metastases,
Early stage disease,
No liver metastases.
Peritoneal metastases,
Adjuvant/neoadjuvant therapy.
Yeager et al. [30] Univariate competing regression modelb Rectal cancer,
RAS mutation,
Lung metastases,
Metastases at diagnosis of CRC.
Surgery.
Kemeny et al. [31] Univariate cumulative incidence function KRAS mutation. None.
Christensen et al. [32] Univariate cox regression None. Primary tumor location,
Age,
Gender,
RAS mutation,
BRAF mutation,
PIK3CA mutation.
Riihimäki et al. [34] Multivariate logistic regression Rectal cancer.
- Colon cancer patients:
Male,
Low age,
Distal opposed to proximal colon.
- Rectal cancer patients:
Low age.
- Colon cancer patients:
Tumor histology
- Rectal cancer patients:
Tumor histology,
Gender
Qui et al. [35] Univariate Chi Square test Rectal cancer,
Lung metastases,
Liver metastases.
None.
Hugen et al. [38] Univariate chi square test Signet-ring cell carcinoma. Primary tumor location.
Katoh et al. [39] Univariate chi square and ﬁsher exact test Signet-ring cell carcinoma,
Liver metastases,
Lung metastases.
Primary tumor location,
Primary tumor grade.
Abbreviations: CRC=Colorectal cancer, CEA=Carcinoembryonic antigen.
a If both univariate and multivariate analysis was performed, only multivariate analysis is presented.
b Multivariate analysis was performed but results of multivariate analysis only presented for RAS status where a positive association was identiﬁed.
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looked at the eﬀect on lymph node metastases developed after primary
surgery.
Six studies (including one autopsy study, one register study, and
three retrospective cohort studies) looked at the association between
bone metastases and lung metastases and all found a signiﬁcantly in-
creased likelihood of BM [15,16,28,30,35,39]. Two of the retrospective
cohort studies presented results of multivariable analysis and identiﬁed
an OR of 2.5–4.8 of BM for patients having lung metastases [15,16].
The remaining studies only performed univariate analysis and found a
2–3 fold increase in incidence of BM among patients who had lung
metastases compared to those who did not [28,30,35,39]. However, a
causal relationship is hard to determine, since none of the studies de-
manded lung metastases to have been diagnosed before BM. Thus,
several studies suggest that patients with rectal primaries are more
likely than patients with colon primaries to present with lung metas-
tases [49,50].
Four not comparable studies have looked at potential associations
between liver metastases and BM with opposite results. Katoh et al. did
in their autopsy study show a signiﬁcantly increased prevalence of liver
metastases among patients with BM compared to patients without BM
[39]. Qui et al., who only included metastases at primary diagnosis,
found a signiﬁcant increased incidence of BM at diagnosis of CRC in
patients who also had liver metastases compared to mCRC patients
without liver metastases [35]. Oppositely, Sundemeyer et al. found a
signiﬁcant decreased incidence of BM among patients with liver me-
tastases compared to patients without in a cohort of mCRC patients
[28]. Lastly, univariate analysis revealed that liver metastases were not
associated with BM in the study by Zhenghong et al. [15].
3.2.5. Gender
Male gender might be associated with increased risk of BM, al-
though results are not conclusive. A large cohort study by Liu demon-
strated a signiﬁcantly higher incidence of BM among male CRC patients
compared to female in univariate analysis [22]. Unfortunately, they did
not adjust for location of primary tumor, which might bias the result.
Male patients have increased incidence of rectum cancer compared to
female patients [34], and the association between gender and BM might
therefor be explained by this. More convincing, Riihimäki et al. de-
monstrated a signiﬁcantly increased risk for BM for males compared to
females among colon cancer patient in a large register study. This as-
sociation remained signiﬁcant when they adjusted for speciﬁc location
in the colon. However, they did not ﬁnd a signiﬁcant association among
rectal cancer patients [34]. Four smaller cohort studies, including a
study conducted by our group, did not demonstrate any association
[15,16,19,32].
This ﬁnding is in contrast with a recent review which concluded
that for lung cancer females might have a more favorable bone mi-
croenvironment for metastasis formation [51]. Anyhow, the diﬀerences
could possibly be the result of statistical variation.
3.2.6. Age of patients
Age might inﬂuence on the risk of developing BM, however, results
are not conclusive. Low age (<60 years) was found to be associated
with a signiﬁcantly higher incidence of BM in the register study by
Riihimäki et al. [34]. Among patients with colon cancer, patients older
than 79 years had an odds ratio (OR) for developing BM of 0.4
(CI 95% = 0.3–0.6) compared to patients younger than 60 years.
Among rectal cancer patients the OR was 0.3 (CI 95% = 0.2–0.4). Four
smaller cohort studies did not ﬁnd any association [16,19,22,32].
The young age could reﬂect a more aggressive disease in younger
patients which leads to BM development [52] or it could be a con-
sequence of older patients with several comorbidities did not receive
treatment and, thus, had fewer evaluations and short OS [53].
3.2.7. Systemic therapies
The impact of systemic anticancer therapy on risk of BM among
patients with CRC is not well investigated, and again ﬁrm conclusions
cannot be drawn. Only the study by Sundemeyer et al. investigated the
potential association between systemic therapies received in the me-
tastatic setting and incidence of BM and found a signiﬁcant association
with high number of systemic therapies, as well as therapy with ir-
inotecan and oxaliplatin compared to patients not receiving these
therapies [28]. Two studies, including the one by Sundemeyer et al.,
looked at whether adjuvant/neoadjuvant therapy aﬀected the like-
lihood of BM but neither found an association [12,28].
3.2.8. Survival
Survival after BM was mentioned in 16 studies. Median overall
survival (OS) after diagnosis of BM ranged from 5 to 21 months
(Table 1).
Median overall survival (OS) after diagnosis of BM ranged from 5 to
21 months (Table 1). However, due to the diﬀerence in time period
patients received treatment and diﬀerent cohorts, a direct comparison
was diﬃcult to make. In the studies that included all patients with CRC
and BM the median OS after BM diagnoses ranged from 7 to 9.4 months
[12–14]. The two register studies by Khattak et al. and Riihimäki et al.
reported a median OS after diagnosis of metastatic disease in patients
who only had BM. They found a median OS of 5.1 [37] and 5.5 months
[34].
Several studies looked at the prognosis for patients with BM com-
pared to patients with other metastases. The results in this regard are
contradictory. The two register studies by Khattak et al. and Riihimäki
et al. observed that mCRC patients with BM only, had signiﬁcantly
worse survival than patients with single site metastases at other sites
such as liver and lung [34,37]. Likewise, Qui et al. did in their large
register study ﬁnd a 1 year cause speciﬁc survival of 29.6% for patients
with BM only compared with 60.2% among patients with liver only and
36.2% among patients with lung only metastases [35]. Oppositely,
three studies found a better prognosis for patients with BM only com-
pared to patients with both BM and visceral metastases [14,22,33].
Five studies presented statistical analysis of factors associated with
poor survival after diagnosis of BM. Summary of their results are found
in Table 3. Several variables were associated with poor survival in-
cluding: osteolytic lesions, more than one bone lesion, rib metastases,
elevated CEA, other metastases, lung metastases and BM at diagnosis of
CRC [12,17,20,22,35]. However, the studies were diﬀerently designed
and used diﬀerent cohorts making a comparison diﬃcult. Furthermore,
the studies all included diﬀerent variables and only a few variables
were included in analyses in more than one study. Therefore, the above
mentioned results should be interpreted with caution, and new studies
are needed to conﬁrm a potential association.
3.3. Treatment
Eight studies described treatment of BM. Treatments used for BM
included bisphosphonate therapy, systemic chemotherapy, radio-
therapy, surgery and medical pain relief [12,14,19–22,40,54]. How-
ever, only three studies analyzed the eﬀect of diﬀerent treatments
(bisphosphonate, radiotherapy and chemotherapy), including two ret-
rospective cohort studies [12,22] and one small randomized study [40].
Summary of the three studies are presented in Table 4.
Bisphosphonate eﬃcacy was statistically evaluated in all three
studies [12,22,40]. The randomized study was a small pilot study and
had several methodological short comings. Firstly, placebo treatment
and randomization were not described. Secondly, no predeﬁned pro-
tocol was described. Thirdly, no comparison of baseline characteristics
was presented between treatment and placebo group and they did not
perform any statistical adjustment for other factors which could have
aﬀected treatment outcome [40]. The incidence of adverse events was
described as comparable to placebo but no analyses was presented [40].
The retrospective studies also had several shortcomings besides the
retrospective nature of the study. In both studies patients received other
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therapies than bisphosphonate for bone metastases during study period,
and neither study did statistically adjust for other factors [12,22].
Though the level of evidence is not high, the studies indicate that
bisphosphonate treatment might improve outcome with regard to ske-
letal-related events (SRE) (deﬁned as pathologic fracture, spinal cord
compression, radiation therapy to bone, change in antineoplastic
therapy and surgery to bone), but not overall survival. No study has
evaluated denosumab in CRC.
This conclusion is consistent with studies on eﬀect of antiresorptive
treatment for BM in lung, breast and prostate cancer, where it has been
shown to reduce skeletal related events (SRE) [7–10].
The eﬀect of other therapies for BM from CRC is poorly investigated.
Only the eﬀect of systemic chemotherapy and radiotherapy has been
analyzed with regard to OS after BM diagnosis, and this was only in one
retrospective cohort study [22]. Systemic chemotherapy was found to
improve survival among BM patients in univariate analysis. However,
most patients also had visceral metastases and the improved survival
might as well be related to the treatment eﬀect on these, indicated by
subgroup analyses of patients with BM as only metastatic site where no
survival beneﬁt was identiﬁed. Furthermore, no association was iden-
tiﬁed in multivariable survival analysis [22].
3.4. Limitations
This study had some limitations. First, we only had access to pub-
lished material from the included studies. Second, in many of the in-
cluded studies it was not possible to determine whether patients were
consecutively included or not. This, in combination with many of the
studies being retrospective, leads to a risk of publication bias. Most of
the present studies contained few BM patients, and did not have suﬃ-
cient strength or the right study design to clarify which factors increase
the risk of BM, or which factors are prognostic. Furthermore, the lit-
erature and quality of studies regarding eﬃcacy treatment for BM from
CRC are sparse, making recommendation in this regard unreliable. This
review highlight the need for new studies about BM. Especially re-
garding treatment for BM from CRC.
4. Conclusion
The literature written about BM from CRC is sparse and hetero-
geneously designed studies make ﬁrm conclusion diﬃcult. BM in pa-
tients with CRC are relatively uncommon disease manifestation, which
occurs in 3–7%. It was not possible to detect an increase in incidence of
BM from CRC and study heterogeneity made conclusions uncertain. The
most well established risk factors for BM are rectal cancer, having
lymph node invasion at surgery of primary tumor, and lung metastases
at any time. Other risk factors have been suggested but results are not
conclusive. Survival ranges from 5 to 21 months after diagnosis of BM
in included studies depending on cohort. Several variables have been
suggested as potential prognostic markers but are all poorly in-
vestigated. Treatments of BM are not well investigated though patients
seem to beneﬁt from bisphosphanate treatment with regard to lower
risk of skeletal related events.
Table 3
Factors associated with poor survival after bone metastases diagnosis
Author Type of analysisa Factors associated
with short
survival after
bone metastases
Other variable included in
analysis but no association
with survival after bone
metastases
Santini
et al.
[12]
Univariate log-
rank test
Osteolytic lesions,
2 or more bone
lesions.
SRE,
Bisphosphanate treatment.
Se-Jin
Baek
et al.
[17]
Multivariable cox
regression
analysis
BoneM from
colon cancer,
Initial bone
metastases.
SRE,
Age,
Gender,
Body mass index.
Jimi et al.
[20]
Multivariable cox
regression
analysis
Lung metastases,
Rib metastases.
Site of primary cancer,
Age,
Gender,
Liver metastases,
Vertebral metastases,
Pelvic metastases,
CEA.
Liu et al.
[22]
Multivariable cox
regression
analysis
Elevated CEA,
Other metastases
at BoneM
diagnosis.
Tumor diﬀerentiation,
Lymphatic metastasis,
Perineural invasion,
Alkaline fosfatase,
Systemic chemotherapy,
Radiotherapy,
Bisphosfanate therapy.
Qui et al.
[35]
Univariate log-
rank test
None. Lung metastases,
Liver metastases.
Abbreviations: SRE= Skeletal related events, CEA=Carcinoembryonic antigen.
a If both univariate and multivariate analysis was performed, only multi-
variate analysis is presented.
Table 4
Treatment of bone metastases
Author End point regarding treatment
eﬃcacy
Treatment of BoneM and comparison
(patients in group)
Results
Santini et al. [12] Time to ﬁrst SRE,
OS.
Zoledronic acid (126) vs no bisphosphonate
therapy (31)
Time to ﬁrst SRE: Signiﬁcantly longer time for Zolodronic acid vs no
bisphosphonate therapy (2 months vs1 months, p = 0.009).
OS: NS.
Liu et al. [22] OS. Bisphosphonate (108) vs. no
bisphosphonate (134),
Radiation therapy (172) vs no radiation
therapy (70),
Chemotherapy (171) vs no chemotherapy
(71),
Combination therapy (192) vs single
therapy (38).
Univariate analysis
Bisphosphonate treatment: NS,
Radiation therapy: NS,
Chemotherapy: Signiﬁcantly (p = 0.012) associated with better OSa,
Combination therapy: Signiﬁcantly (p= 0.01) associated with better OSa
Multivariate analysis
Chemotherapy: NS.
Heras et al. [40] Primary endpoint:
Proportion with SRE.
Secondary endpoint:
time to SRE,
events per year,
time to progression of bone
lesion.
Ibandronate treatment vs placebo. Ibandronate signiﬁcantly superior to placebo regarding:
Proportion with SRE (39 % vs. 78 %, p = 0.019),
Time to ﬁrst SRE (214 days vs 81 days, p=0.009),
SRE per year (2.36 vs 3.14, p = 0.018),
Time to progression of bone lesion (214 days vs 81 days, p = 0.018).
Abbreviations: SRE=Skeletal related events, deﬁned as pathologic fracture, spinal cord compression, radiation therapy to bone, change in antineoplastic therapy and
surgery to bone, OS=Overall survival, NS=No signiﬁcant association, BM=Bone metastases.
a Eﬀect size not reported.
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This review highlight the need for new studies about BM from CRC.
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